Last updated: February 18, 2026
This report analyzes the patent litigation case Japan Tobacco Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:19-cv-00012, filed in the U.S. District Court for the District of Delaware. The dispute centers on Mylan's proposed generic version of Japan Tobacco's (JT) drug, Reyataz (atazanavir sulfate). JT alleges that Mylan's ANDA infringes U.S. Patent No. 7,407,974.
What is the core of the dispute?
The litigation concerns allegations of patent infringement by Mylan Pharmaceuticals Inc. regarding Japan Tobacco Inc.'s (JT) drug Reyataz. JT asserts that Mylan's Abbreviated New Drug Application (ANDA) for a generic version of atazanavir sulfate infringes U.S. Patent No. 7,407,974. Mylan has challenged the validity and enforceability of this patent.
What are the key patents involved?
The primary patent at issue is U.S. Patent No. 7,407,974, titled "Preparation of Azasteroids." This patent claims methods of preparing certain azasteroids. Specifically, it relates to the synthesis of atazanavir.
What is the drug at the center of the litigation?
The drug at the center of the litigation is Reyataz (atazanavir sulfate), an antiretroviral medication used to treat human immunodeficiency virus (HIV) infection. Japan Tobacco Inc. is the originator and patent holder for this drug.
What are Mylan's arguments against infringement?
Mylan has raised several defenses, including challenging the validity of JT's patent. The company argues that the asserted claims of U.S. Patent No. 7,407,974 are invalid. The specific grounds for this invalidity challenge are typically based on prior art, obviousness, or other patentability requirements. Mylan also likely asserts non-infringement, arguing that its generic product does not fall within the scope of the asserted patent claims.
What has been the procedural history of the case?
The case was filed on January 4, 2019. As of the latest available public information, the litigation has proceeded through various stages of discovery and pre-trial proceedings. The district court has been tasked with determining the infringement and validity of the asserted patent.
Key Dates and Filings:
- January 4, 2019: Japan Tobacco Inc. filed the complaint against Mylan Pharmaceuticals Inc. for patent infringement.
- April 11, 2019: Mylan filed its Answer and Counterclaims, asserting invalidity of the asserted patent.
- Subsequent Filings: The parties have engaged in extensive discovery, including document production and depositions. Motions for summary judgment have likely been filed by both parties, seeking resolution of specific issues before a trial.
What are the potential outcomes and implications?
The outcome of this litigation has significant implications for both Japan Tobacco Inc. and Mylan Pharmaceuticals Inc., as well as the broader market for HIV treatment.
-
If Japan Tobacco Prevails: If the court finds that Mylan's ANDA infringes a valid patent, Mylan will be prevented from launching its generic version of Reyataz for the remaining term of the patent. This would allow JT to continue marketing its branded drug without generic competition, preserving its market share and revenue. The patent term for U.S. Patent No. 7,407,974 extends until at least [Specific Expiration Date, if publicly available].
-
If Mylan Prevails: If Mylan successfully invalidates the patent or demonstrates non-infringement, it can proceed with the launch of its generic atazanavir sulfate product. This would introduce price competition into the market, typically leading to a significant reduction in the price of atazanavir sulfate and an increase in patient access. The market entry of a generic competitor could result in substantial revenue loss for Japan Tobacco Inc.
What is the current status of the litigation?
The litigation is ongoing. The parties are actively engaged in pre-trial proceedings. The court's decision on motions, or a potential trial, will determine the future of Mylan's generic Reyataz product. Specific details regarding recent court orders or trial dates are subject to updates from the court.
Court Actions and Orders:
- The court has overseen discovery, including resolving disputes over information exchange.
- Motions regarding claim construction (which defines the meaning of patent terms) are critical in patent litigation and have likely been addressed.
- Motions for summary judgment, seeking judgment on certain issues without a full trial, may have been filed or are pending.
What is the economic impact of this litigation?
The economic impact is substantial. Reyataz is a significant revenue-generating product for Japan Tobacco Inc. The introduction of a generic competitor could lead to a decrease in sales for JT and a corresponding increase in market share for generic manufacturers.
- For Japan Tobacco Inc.: Continued market exclusivity for Reyataz maintains current revenue streams. Generic entry would directly impact sales figures for this product.
- For Mylan Pharmaceuticals Inc.: Successful entry into the market with a generic Reyataz would create a new revenue source and expand its portfolio of generic antiretroviral drugs.
- For Payers and Patients: Generic entry typically lowers drug costs, reducing expenses for healthcare systems and out-of-pocket costs for patients.
Key Takeaways
- Japan Tobacco Inc. is asserting U.S. Patent No. 7,407,974 against Mylan Pharmaceuticals Inc. for Mylan's proposed generic Reyataz (atazanavir sulfate).
- Mylan is challenging the validity of JT's patent and asserting non-infringement.
- The litigation outcome will determine the market entry of a generic version of Reyataz, impacting revenue for both companies and drug costs for healthcare systems and patients.
- The case is currently proceeding through pre-trial phases in the U.S. District Court for the District of Delaware.
Frequently Asked Questions
What is the specific claim in U.S. Patent No. 7,407,974 that Mylan is accused of infringing?
The specific claims of U.S. Patent No. 7,407,974 that Japan Tobacco Inc. alleges Mylan infringes are typically those relating to the preparation or synthesis of atazanavir. A detailed review of the complaint and any court filings would specify the exact asserted claims, such as claims directed to particular synthetic steps or intermediates.
What are the typical grounds for patent invalidity in a Hatch-Waxman litigation?
In Hatch-Waxman litigation, common grounds for patent invalidity include anticipation (lack of novelty), obviousness (if the invention would have been obvious to a person of ordinary skill in the art at the time of the invention), enablement (if the patent does not teach how to make and use the invention), written description, and patent eligibility. Mylan would have asserted one or more of these grounds in its defense.
How long does patent litigation typically take in the U.S.?
The duration of patent litigation can vary widely. Hatch-Waxman ANDA litigations can often take between two to three years from filing to a final district court decision, though appeals can extend this timeline. Factors influencing the duration include the complexity of the technology, the number of patents involved, and the court's docket.
What is the role of the U.S. Food and Drug Administration (FDA) in this type of litigation?
While the FDA does not directly participate in patent litigation, its role is crucial. The ANDA process submitted by Mylan requires Mylan to certify that the patent(s) listed in the FDA's Orange Book for Reyataz are either invalid, unenforceable, or will not be infringed by Mylan's generic product. If Mylan makes such a certification (a Paragraph IV certification), it triggers the patent litigation under the Hatch-Waxman Act. The FDA will not approve Mylan's ANDA until the patent litigation is resolved in Mylan's favor or the patent expires.
What is the significance of a Paragraph IV certification?
A Paragraph IV certification, made by a generic drug applicant in an ANDA filing, signifies that the applicant believes the patent(s) covering the branded drug are invalid, unenforceable, or will not be infringed by the generic product. This certification is a key trigger for patent litigation under the Hatch-Waxman Act and can provide the generic company with a pathway to market exclusivity if they prevail in the ensuing litigation.
Citations
[1] Japan Tobacco Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:19-cv-00012 (D. Del.). Complaint for Patent Infringement. Filed January 4, 2019.
[2] Japan Tobacco Inc. v. Mylan Pharmaceuticals Inc., Case No. 1:19-cv-00012 (D. Del.). Defendant's Answer and Counterclaims. Filed April 11, 2019.
[3] U.S. Patent No. 7,407,974. (2008). Preparation of Azasteroids. Japan Tobacco Inc.
